Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study

BackgroundProprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) exhibit promising lipid-lowering activity, but evidence regarding their effectiveness in real-world diabetic populations is limited.MethodsBased on TriNetX database, individuals T2D and dyslipidemia who were newly prescribe...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Jheng-Yan Wu, Yu Min Lin, Wan-Hsuan Hsu, Tinghui Liu, Ya-Wen Tsai, Po-Yu Huang, Min Hsiang Chuang, Tsung Yu, Chih-Cheng Lai
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2025-11-01
סדרה:	Frontiers in Endocrinology
נושאים:	PCSK9 inhibitor type 2 diabetes All-cause mortality major adverse cardiovascular event major adverse kidney event
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1709009/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!